Last reviewed · How we verify
NCT07104890: ERAS-CS
Enhanced Recovery After Surgery (ERAS) Protocol in Elective Cesarean Sections
NA trial testing Enhanced Recovery After Surgery (ERAS) Protocol, which includes early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early urinary catheter removal, an in Elective Cesarean Section in 84 participants. Completed in 1 December 2022.
1 November 2022
Quick facts
| Lead sponsor | Havva Betül Bacak |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 84 |
| Start date | 1 October 2022 |
| Primary completion | 1 November 2022 |
| Estimated completion | 1 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Enhanced Recovery After Surgery (ERAS) Protocol, which includes early oral intake, early mobilization, opioid-sparing multimodal analgesia, prophylactic antiemetics, early urinary catheter removal, an
Conditions studied
- Elective Cesarean Section — all drugs for Elective Cesarean Section →
- Postoperative Recovery — all drugs for Postoperative Recovery →
- Enhanced Recovery After Surgery (ERAS) — all drugs for Enhanced Recovery After Surgery (ERAS) →
Sponsor
Havva Betül Bacak — full company profile →
Who can join
18 and older, female only, with Elective Cesarean Section or Postoperative Recovery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study evaluates the effect of the Enhanced Recovery After Surgery (ERAS) protocol on early postoperative recovery in women undergoing elective cesarean section. Eighty-four pregnant women, aged 18 years or older, at 37 weeks of gestation or beyond, without chronic medical conditions, and classified as ASA I-II, were enrolled. Participants were randomly assigned to either: ERAS group - received the ERAS protocol, including early oral intake, early mobilization, multimodal analgesia, and enhanced perioperative care Control group - received standard perioperative cesarean section care The study compared breastfeeding initiation time, gas passage, oral intake, mobilization time, and postoperative pain scores (VAS) between the two groups. The aim is to determine whether ERAS can accelerate recovery, reduce pain, and improve maternal comfort after elective cesarean delivery.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07104890
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Elective Cesarean Section
Currently open trials in the same condition.
- NCT07406373 — Intra-abdominal Pressure, Abdominal Circumference, and Spinal Block Level in Cesarean Section · recruiting
Other Havva Betül Bacak trials
Trials by the same sponsor.
- NCT07248579 — Turkish Validation of the Pregnancy-Specific Anxiety Tool (PSAT) · completed
- NCT07426666 — Vaginal Cuff Bupivacaine Injection for Postoperative Pain · NA · completed
- NCT07082023 — Comparison of V-NOTES and Laparoscopic Mesh-Free Sacrocolpopexy Techniques · NA · recruiting
- NCT07248540 — IV Magnesium in the Treatment of Acute Dysmenorrhea · NA · recruiting
- NCT07094776 — Evaluation of MG53 (TRIM72) Levels in Women With Polycystic Ovary Syndrome: An Observational Study · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07104890 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Havva Betül Bacak
- Last refreshed: 5 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07104890.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing